Very high-dose methotrexate (33.6 g/m²) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute/Children's Cancer Group trials CCG-191P, CCG-134P and CCG-144P

References

• Ries L AG, Eisner M P, Kosary C L, Hankey B F, Miller B A, Clegg L, et al. SEER Cancer Statistics Review, 1975 – 2000. National Cancer Institute, Bethesda, MD 2003
   Google Scholar
• Jankovic M, Brouwers P, Valsecchi M G, Van Veldhuizen A, Huisman J, Kamphuis R, et al. Association of 1800 cGy cranial irradiation with intellectual function in children with acute lymphoblastic leukaemia. ISPACC. International Study Group on Psychosocial Aspects of Childhood Cancer. Lancet 1994; 344: 224–227
   PubMed Web of Science ®Google Scholar
• Howard S C, Pui C H. Endocrine complications in pediatric patients with acute lymphoblastic leukemia. Blood Rev 2002; 16: 225–243
   PubMed Web of Science ®Google Scholar
• Relling M V, Rubnitz J E, Rivera G K, Boyett J, Hancock M L, Felix C, et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 1999; 354: 34–39
   PubMed Web of Science ®Google Scholar
• Pui C H, Cheng C, Leung W, Rai S N, Rivera G K, Sandlund J T, et al. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med 2003; 349: 640–649
   PubMed Web of Science ®Google Scholar
• Perel Y, Leverger G, Carrere A, Caudry M, Garabedian E N, Ansoborlo S, et al. Second thyroid neoplasms after prophylactic cranial irradiation for acute lymphoblastic leukemia. Am J Hematol 1998; 59: 91–94
   PubMed Web of Science ®Google Scholar
• Nesbit M E, Jr, Sather H N, Robison L L, Ortega J, Littman P S, D'Angio G J, et al. Presymptomatic central nervous system therapy in previously untreated childhood acute lymphoblastic leukaemia: comparison of 1800 rad and 2400 rad. A report for Children's Cancer Study Group. Lancet 1981; 1: 461–466
   PubMed Web of Science ®Google Scholar
• Bleyer W A, Poplack D. Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries. Semin Oncol 1985; 12: 131–148
   PubMed Web of Science ®Google Scholar
• Balis F M, Blaney S M, McCully C, Bacher J D, Murphy R F, Poplack D G. Methotrexate distribution within the subarachnoid space after intraventricular and intravenous administration. Cancer Chemother Pharmacol 2000; 45: 259–264
   PubMed Web of Science ®Google Scholar
• Shapiro W R, Young D F, Mehta B M. Methotrexate: distribution in cerebrosopinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975; 293: 161–166
   PubMed Web of Science ®Google Scholar
• Hryniuk W M, Bertino J R. Treatment of leukemia with large doses of methotrexate and folinic acid: clincial-biochemical correlates. J Clin Invest 1969; 48: 2140–2155
   PubMed Web of Science ®Google Scholar
• Bleyer W A, Poplack D. Clinical studies on the central-nervous-system pharmacology of methotrexate. Clinical Pharmacology of Anti-Neoplastic Drugs, H M Pinedo. Elsevier/North Holland Biomedical, Amsterdam 1978; 115–131
   Google Scholar
• Morse M, Savitch J L, Balis F M, Miser J, Feusner J, Reaman G, et al. Altered central-nervous-system pharmacology of methotrexate in childhood leukemia: another sign of meningeal relapse. J Clin Oncol 1985; 3: 19–24
   PubMed Web of Science ®Google Scholar
• Balis F M, Savitch J L, Bleyer W A, Reaman G H, Poplack D G. Remission induction of meningeal leukemia with high-dose intravenous methotrexate. J Clin Oncol 1985; 3: 485–489
   PubMed Web of Science ®Google Scholar
• McCarthy D. McCarthy Scales of Children's Abilities. Psychological Corporation, San Antonio, TX 1972
   Google Scholar
• Wechsler D. Wechsler Intelligence Scale for Children – Revised. Psychological Corporation, San Antonio, TX 1974
   Google Scholar
• Wechsler D. Wechsler Adult Intelligence Scale. The Psychological Corporatoin, New York, NY 1955
   Google Scholar
• Wechsler D. Wechsler Adult Intelligence Scale – Revised. Psychological Corporation, San Antonio, TX 1981
   Google Scholar
• Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 103
   Google Scholar
• Laird N M, Ware J H. Random-effects models for longitudinal data. Biometrics 1982; 38: 963–974
   PubMed Web of Science ®Google Scholar
• Smith M, Arthur D, Camitta B, Carroll A J, Crist W, Gaynon P, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996; 14: 18–24
   PubMed Web of Science ®Google Scholar
• Nachman J, Sather H N, Cherlow J M, Sensel M G, Gaynon P S, Lukens J N, et al. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group. J Clin Oncol 1998; 16: 920–930
   PubMed Web of Science ®Google Scholar
• Hill F, Richards S, Hann I, Gibson B, Lilleyman J, Kinsey S, et al. Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukemia: results of a risk-stratified randomized central nervous system treatment trial MRC UKALL XI. Br J Haematol 2004; 124: 33–46
   PubMed Web of Science ®Google Scholar
• Gaynon P, Trigg M, Heerema N A, Sensel M G, Sather H, Hammond G D, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983 – 1995. Leukemia 2000; 14: 2223–2233
   PubMed Web of Science ®Google Scholar
• Clarke M, Gaynon P, Hann I, Harrison G, Masera G, Peto R, et al. CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group Overview of 43 randomized trials. J Clin Oncol 2003; 21: 1798–1809
   PubMed Web of Science ®Google Scholar
• Moe P J, Holen A, Nygaard R, Glomstein A, Madsen B, Hellebostad M, et al. Methotrexate infusions as central nervous system prophylaxis in children with acute lymphoblastic leukemia: the Norwegian experience. Pediatr Hematol Oncol 2003; 20: 187–200
   PubMed Web of Science ®Google Scholar
• Camitta B, Mahoney D, Leventhal B, Lauer S J, Shuster J, Adair S, et al. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: a Pediatric Oncology Group study. J Clin Oncol 1994; 12: 1383–1389
   PubMed Web of Science ®Google Scholar
• Kamps W A, Bokkerink J P, Hahlen K, Hermans J, Riehm H, Gadner H, et al. Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988 – 1991). Blood 1999; 94: 1226–1236
   PubMed Web of Science ®Google Scholar
• Silverman L B, Gelber R D, Dalton V K, Asselin B L, Barr R D, Clavell L A, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001; 97: 1211–1218
   PubMed Web of Science ®Google Scholar
• Pui C H, Sandlund J T, Pei D, Campana D, Rivera G K, Ribeiro R C, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 2004; 104: 2690–2696
   PubMed Web of Science ®Google Scholar
• Pui C H, Evans W E. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166–178
   PubMed Web of Science ®Google Scholar
• Burger B, Zimmermann M, Mann G, Kuhl J, Loning L, Riehm H, et al. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol 2003; 21: 184–188
   PubMed Web of Science ®Google Scholar
• Moore B D, III. Neurocognitive outcomes in survivors of childhood cancer. J Pediatr Psychol 2005; 30: 51–63
   PubMed Web of Science ®Google Scholar
• Copeland D R, Fletcher J M, Pfefferbaum-Levine B, Jaffe N, Ried H, Maor M. Neuropsychological sequelae of childhood cancer in long-term survivors. Pediatrics 1985; 75: 745–753
   PubMed Web of Science ®Google Scholar
• Mulhern R K, Fairclough D, Ochs J. A prospective comparison of neuropsychologic performance of children surviving leukemia who received 18-Gy, 24-Gy, or no cranial irradiation. J Clin Oncol 1991; 9: 1348–1356
   PubMed Web of Science ®Google Scholar
• Rowland J H, Glidewell O J, Sibley R F, Holland J C, Tull R, Berman A, et al. Effects of different forms of central nervous system prophylaxis on neuropsychologic function in childhood leukemia. J Clin Oncol 1984; 2: 1327–1335
   PubMed Web of Science ®Google Scholar
• Trautman P D, Erickson C, Shaffer D, O'Connor P A, Sitarz A, Correra A, et al. IS. Prediction of intellectual deficits in children with acute lymphoblastic leukemia. J Dev Behav Pediatr 1988; 9: 122–128
   PubMed Web of Science ®Google Scholar
• Brown R T, Madan-Swain A, Pais R, Lambert R G, Baldwin K, Casey R, et al. Cognitive status of children treated with central nervous system prophylactic chemotherapy for acute lymphocytic leukemia. Arch Clin Neuropsychol 1992; 7: 481–497
   PubMed Web of Science ®Google Scholar
• Brown R T, Sawyer M G, Antoniou G, Rice M. Longitudinal follow-up of the intellectual and academic functioning of children receiving central nervous system-prophylactic chemotherapy for leukemia: a four-year final report. Dev Behav Pediatr 1999; 20: 373–377
   PubMed Web of Science ®Google Scholar
• Reaman G H, Sposto R, Sensel M G, Lange B J, Feusner J H, Heerema N A, et al. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. J Clin Oncol 1999; 17: 445–455
   PubMed Web of Science ®Google Scholar
• Evans W E, Pui C H, Relling M V. Defining the optimal dosage of methotrexate for childhood acute lymphoblastic leukemia. Drug Resistance in Leukemia and Lymphoma III, G J Kaspers, R Pieters, A J Veerman. Kluwer Academic/Plenum Publishers, New York, NY 1999; 537–541
   Google Scholar
• Evans W E, Crom W R, Abromowitch M, Dodge R, Look A T, Bowman W P, et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med 1986; 314: 471–477
   PubMed Web of Science ®Google Scholar
• Camitta B, Leventhal B, Lauer S, Shuster J J, Adair S, Casper J, et al. Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study. J Clin Oncol 1989; 7: 1539–1544
   PubMed Web of Science ®Google Scholar
• Evans W E, Schell M J, Pui C H. MTX clearance is more important for intermediate-risk ALL. J Clin Oncol 1990; 8: 1115–1119
   PubMed Web of Science ®Google Scholar
• Keefe D A, Capizzi R L, Rudnick S A. Methotrexate cytotoxicity for L5178Y/Asn- lymphoblasts: relationship of dose and duration of exposure to tumor cell viability. Cancer Res 1982; 42: 1641–1645
   PubMed Web of Science ®Google Scholar
• Schrappe M, Reiter A, Henze G, Niemeyer C, Bode U, Kuhl J, et al. Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials. Klinische Padiatrie 1998; 210: 192–199
   PubMed Web of Science ®Google Scholar
• Littman P, Coccia P, Bleyer W A, Lukens J, Siegel S, Miller D, et al. Central nervous system (CNS) prophylaxis in children with low risk acute lymphoblastic leukemia (ALL). Int J Radiat Oncol Biol Phys 1987; 13: 1443–1449
   PubMed Web of Science ®Google Scholar
• Conter V, Arico M, Valsecchi M G, Rizzari C, Testi A M, Messina C, et al. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Munster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica. J Clin Oncol 1995; 13: 2497–2502
   PubMed Web of Science ®Google Scholar
• Tubergen D G, Gilchrist G S, O'Brien R T, Coccia P F, Sather H N, Waskerwitz M J, et al. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Childrens Cancer Group report. J Clin Oncol 1993; 11: 520–526
   PubMed Web of Science ®Google Scholar